Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis

British Journal of Clinical Pharmacology

Volumn 41, Issue 5, 1996, Pages 421-424

  Bendriss, E K ^a   Bechtel, Y ^a   Bendriss, A ^a   Humbert, Ph ^a   Paintaud, G ^a   Magnette, J ^a,b   Agache, P ^a   Bechtel, P R ^a,c  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b Med Pharex S A   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

5 methoxypsoralen; caffeine; CYP1A2; inhibition; metabolism

Indexed keywords

BERGAPTEN; CAFFEINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS;

EID: 0029883549     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.33311.x     Document Type: Article

References (26)

1. Mays DC, Camisa C, Cheney P, Pacula CM, Nawoot S, Gerber N. Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. Clin Pharmacol Ther 1987; 42: 621-626.
2. Apseloff G, Shepard DR, Chambers MA, Nawoot S, Mays DC, Gerber N. Inhibition and induction of theophylline metabolism by 8-methoxypsoralen: in vivo study in rats and humans. Drug Metab Dispos 1990; 18: 298-303.
3. Hönigsmann H, Jaschke E, Gschnait F, Brenner W, Fritsch P, Wolff K. 5-methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. Br J Dermatol 1979; 101: 369-378.
4. Kalis B, Sayag S, Forlot P. Photochemotherapy (PUVA) of psoriasis: a double-blind comparative study of 5- and 8-methoxypsoralen. In Psoralens: past present and future of photochemoprotection and other biological activities, eds Fitzpatrick TB, Forlot P, Pathak MA, Urbach F, Paris: John Libbey Eurotext, 1988: 277-282.
5. Tanew A, Ortel B, Rappersberger K, Höningsmann H. 5-methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation. J Am Acad Dermatol 1988; 18: 333-338.
6. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591-602.
7. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-165.
8. Bechtel Y, Joanne C, Grandmottet M, Bechtel P. The influence of insulin-dependent diabetes on the metabolism of caffeine and the expression of the debrisoquin oxidation phenotype. Clin Pharmacol Ther 1988; 44: 408-417.
9. Arnaud MJ . Metabolism of caffeine and other components of coffee. In Caffeine, Coffee and Health, ed Garattini S, New York: Raven Press Ltd, 1993: 43-95.
10. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503-514.
11. Herfst MJ, Edelbroek PM, De Wolff FA. Determination of 8-methoxypsoralen in suction-blister fluid and serum by liquid chromatography. Clin Chem 1980; 26: 1825-1828.
12. Brazier JL, Descotes J, Lery N, Ollagnier M, Evreux J-CI. Inhibition by idrocilamide of the disposition of caffeine. Eur J Clin Pharmacol 1980; 17: 37-43.
13. Stolk LML, Westerhof W, Cormane RH, Van Zwieten PA. Serum and urine concentrations of 5-methoxypsoralen after oral administration. Br J Dermatol 1981; 105: 415-420.
14. Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983; 24: 93-98.
15. Fouin-Fortunet H, Tinel M, Descatoire V, et al. Inactivation of cytochrome P-450 by the drug methoxsalen. J Pharmacol Exp Ther 1986; 236: 237-247.
16. Tinel M, Belghiti J, Descatoire V, et al. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem Pharmacol 1987; 36: 951-955.
17. Cheng WSC, Murphy TL, Smith MT, Cooksley WGE, Halliday JW, Powell LW. Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function. Clin Pharmacol Ther 1990; 47: 516-524.
18. Denaro CP, Brown CR, Wilson M, Jacob III P, Benowitz NL. Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 1990; 48: 277-285.
19. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401-407.
20. Levy M, Zylber-Katz E. Caffeine metabolism and coffee-attributed sleep disturbances. Clin Pharmacol Ther 1983; 33: 770-775.
21. McEvoy MT, Stern RS. Psoralens and related compounds in the treatment of psoriasis. Pharmacol Ther 1987; 34: 75-97.
22. Lake CR, Rosenberg DB, Gallant S, Zaloga G, Chernow B. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 1990; 47: 675-685.
23. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br J Clin Pharmacol 1990; 29: 351-363.
24. Tarrus E, Cami J, Roberts DJ, Spickett RGW, Celdran E, Segura J. Accumulation of caffeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 1987; 23: 9-18.
25. Brason K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
26. Catteau A, Bechtel Y, Poisson N, Bechtel P, Bonaiti-Pellie C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47: 423-430.